S

Sanofi

Global pharma company; vaccines and R&D

Credit Collection Senior Analyst - Japanese Speaker

Full-TimeUpdated on 10/15/2026Deadline 10/31/26
No salary listed
Senior
Bachelor's
Petaling Jaya, Selangor, Malaysia
HybridFlexible home office policy allows working from home up to 50% of the time.
AccountingAccounts Payable/Receivable

About the job

Requirements
  • Excellent written and verbal skills in Japanese and English.
  • A minimum of 5 years of relevant work experience in the finance or accounting sector.
  • Previous accounting or finance experience, particularly in a shared-services environment, is advantageous, especially in a pharmaceutical environment.
  • Ability to assess, analyze, and validate complex financial information.
  • Thorough knowledge of accounting and credit principles, systems, and procedures.
  • Familiarity with a matrix organization.
  • Good business acumen is advantageous.
  • Strong problem-solving and deductive reasoning skills are advantageous.
  • Exposure to Lean/Six Sigma or equivalent is desired.
  • Experience with SAP, specifically FICO, is preferred; experience with SAP Application Interface Framework modules is advantageous.
  • Previous use of an optical character recognition solution is advantageous.
  • Understanding of shared-services technologies such as scanning and imaging, case management tools, KPI monitoring, and reporting is preferred.
  • Knowledge of Microsoft Office, with expertise in Microsoft Excel and PowerPoint, is essential.
  • Ability to interact with internal stakeholders to resolve issues is essential.
  • Ability to work collaboratively across functions and with frontline teams, with an end-to-end mindset, is essential.
  • Good communication skills are essential.
  • Ability to work independently and in a metrics-driven environment.
  • Minimum qualification: a Bachelor's Degree, Post Graduate Diploma, or Professional Degree in Accounting, Finance, or Business, or equivalent.
  • Ability to speak and write Mandarin is a plus.
Responsibilities
  • Deliver Credit and Collections management services to SBO according to service level agreements.
  • Review accounts receivable ageing reports; perform collections and dunning; and escalate and follow up on actions.
  • Address operational issues and follow through to resolution effectively and promptly.
  • Check credit availability and manage blocked sales orders related to overdue accounts.
  • Assess new-customer credit risk and customer-portfolio risk.
  • Perform ad hoc reviews of customer credit data.
  • Contribute to periodic reviews and updates of credit policies, guidelines, and the credit-management operational framework.
  • Deliver operational key performance indicators and comply with company policies and guidelines.
  • Participate in continuous-improvement initiatives.
  • Deliver Credit and Collections services in accordance with agreed service level agreements, ensuring operational excellence, customer satisfaction, and compliance with global standards.
  • Manage end-to-end Credit and Collections activities, including accounts receivable collections, dunning, ageing review, dispute follow-up, credit assessments, credit-limit reviews, blocked sales-order management, and portfolio-risk monitoring.
  • Serve as the subject matter expert for Credit Management and Collection management processes, guide resolution of complex operational issues, and ensure consistent application of the O2C Core Model.
  • Exercise delegated credit authorization up to the approved authority limit by evaluating customer risk and making credit decisions that balance commercial objectives and financial risk.
  • Deliver operational key performance indicators, including sales orders released, overdue reduction, on-time cash collection, and service performance, through proactive portfolio management and effective execution.
  • Investigate operational issues and drive timely resolution by coordinating with internal stakeholders, commercial teams, customers, and neighboring functions.
  • Support monthly or quarterly credit committee activities through analysis of portfolio performance, overdue trends, risk exposure, and recommended mitigation actions.
  • Lead or participate in projects, system enhancements, automation initiatives, process optimization, and business-transformation activities to improve operational efficiency and customer experience.
  • Manage projects and additional assignments delegated by management, ensuring timely execution and successful delivery.
  • Support the Team Lead or manager in day-to-day operational supervision, workload planning, resource allocation, and business-continuity planning.
  • Coordinate team activities to support service-level agreement achievement, operational consistency, and effective knowledge sharing across the team.
  • Provide coaching, mentoring, and technical guidance to Analysts and Senior Analysts, acting as the first point of escalation for operational issues.
  • Foster a collaborative, high-performing, and continuous-improvement culture within the team.
  • Build partnerships with Commercial, Finance, Supply Chain, Treasury, O2S, and other cross-functional stakeholders to achieve business objectives.
  • Engage with external and internal customers to resolve collection issues, credit concerns, payment disputes, and other operational matters.
  • Collaborate with Global Process Owners, Regional Process Teams, Digital/ITS teams, and project teams to support global initiatives and process standardization.
  • Present recommendations and provide business insights to stakeholders across organizational levels.
  • Ensure compliance with company policies, internal controls, SOX requirements, local credit policies, VAT and legal requirements, and Records Management standards.
  • Support internal and external audits, control self-assessments, risk reviews, and implementation of corrective actions.
  • Identify financial, operational, and compliance risks; recommend mitigation plans; and monitor execution.
  • Maintain governance through accurate documentation, process controls, and adherence to global operating procedures.
  • Act as an O2C subject matter expert supporting implementation and evolution of the Global Core Model or Target Operating Model.
  • Support deployment of strategic business initiatives, ERP implementations, digital transformation, automation, and process-harmonization projects.
  • Identify process gaps, standardization opportunities, and best practices to improve efficiency, consistency, governance, and customer experience.
  • Collaborate with Global Process Owners and Regional Process Management teams to implement standard processes, manage deviations, and drive sustainable process improvements.
  • Champion continuous improvement by collecting ideas, developing implementation plans, and overseeing delivery of operational-excellence initiatives.
Desired Qualifications
  • Previous accounting or finance experience in a shared-services environment, especially in a pharmaceutical environment.
  • Good business acumen.
  • Strong problem-solving and deductive reasoning skills.
  • Exposure to Lean/Six Sigma or equivalent.
  • Experience with SAP FICO; SAP Application Interface Framework modules are advantageous.
  • Previous use of an optical character recognition solution.
  • Understanding of shared-services technologies such as scanning and imaging, case management tools, KPI monitoring, and reporting.
  • Mandarin language skills, both verbal and written.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)